Recombinant adenovirus vectors enable highly efficient gene delivery in vitro and in vivo. As a result, they are widely used in gene therapy, vaccination, and anticancer applications. We have previously developed the AdZ vector system, which uses recombineering to permit high-throughput cloning of transgenes into Adenovirus vectors, simplifies alteration of the vector backbone, and enables rapid recovery of infectious virus, even if a transgene is incompatible with vector replication. In this study, we adapt this vector system to enable high-throughput cloning of sequences for CRISPR/Cas9 editing. Vectors were optimized to ensure efficient cloning, and high editing efficiency using spCas9 and single guide RNA (sgRNA) sequences in a single vector. Using a multiplicity of infection of 50, knockout efficiencies of up to 80% could be achieved with a single sgRNA. Vectors were further enhanced by altering the spCas9 sequence to match that of SniperCas9, which has reduced off-target activity, but maintains on-target efficiency, and by applying modifications to the sgRNA sequence that significantly enhance editing efficiency. Thus, the AdZ-CRISPR vectors offer highly efficient knockout, even in hard to transfect cells, and enables large-scale CRISPR/Cas9 projects to be undertaken easily and quickly.
Get full access to this article
View all access options for this article.
References
1.
AdliM. The CRISPR tool kit for genome editing and beyond. Nat Commun, 2018; 9:1911.
2.
JinekM, ChylinskiK, FonfaraI, et al.A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 2012; 337:816–821.
3.
JinekM, EastA, ChengA, et al.RNA-programmed genome editing in human cells. Elife, 2013; 2:e00471.
4.
CongL, RanFA, CoxD, et al.Multiplex genome engineering using CRISPR/Cas systems. Science, 2013; 339:819–823.
5.
MaliP, YangL, EsveltKM, et al.RNA-guided human genome engineering via Cas9. Science, 2013; 339:823–826.
6.
ShirleyJL, de JongYP, TerhorstC, et al.Immune responses to viral gene therapy vectors. Mol Ther, 2020; 28:709–722.
7.
SchmidtMJ, GuptaA, BednarskiC, et al.Improved CRISPR genome editing using small highly active and specific engineered RNA-guided nucleases. Nat Commun, 2021; 12:4219.
8.
IbraheimR, TaiPWL, MirA, et al.Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo. Nat Commun, 2021; 12:6267.
9.
BoucherP, CuiX, CurielDT. Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors. J Controll Release, 2020; 327:788–800.
10.
WangD, MouH, LiS, et al.Adenovirus-mediated somatic genome editing of Pten by CRISPR/Cas9 in mouse liver in spite of Cas9-specific immune responses. Hum Gene Ther, 2015; 26:432–442.
11.
KreppelF, HagedornC. Capsid and genome modification strategies to reduce the immunogenicity of adenoviral vectors. Int J Mol Sci, 2021; 22:2417.
12.
DavisonAJ, BenkoM, HarrachB. Genetic content and evolution of adenoviruses. J Gen Virol, 2003; 84:2895–2908.
13.
GrahamFL, SmileyJ, RussellWC, et al.Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol, 1977; 36:59–74.
14.
FallauxFJ, BoutA, van der VeldeI, et al.New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther, 1998; 9:1909–1917.
15.
McGroryWJ, BautistaDS, GrahamFL. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology, 1988; 163:614–617.
16.
BettAJ, HaddaraW, PrevecL, et al.An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci U S A, 1994; 91:8802–8806.
17.
NgP, CummingsDT, EveleghCM, et al.Yeast recombinase FLP functions effectively in human cells for construction of adenovirus vectors. Biotechniques, 2000; 29:524–526, 528.
18.
NgP, ParksRJ, CummingsDT, et al.An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method. Hum Gene Ther, 2000; 11:693–699.
19.
StantonRJ, McSharryBP, ArmstrongM, et al.Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function. Biotechniques, 2008; 45:659–662, 664–658.
20.
YuD, EllisHM, LeeEC, et al.An efficient recombination system for chromosome engineering in Escherichia coli. Proc Natl Acad Sci U S A, 2000; 97:5978–5983.
21.
WarmingS, CostantinoN, CourtDL, et al.Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res, 2005; 33:e36.
22.
FieldingCA, AichelerR, StantonRJ, et al.Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation. PLoS Pathog, 2014; 10:e1004058.
23.
StantonRJ, Prod'hommeV, PurbhooMA, et al.HCMV pUL135 remodels the actin cytoskeleton to impair immune recognition of infected cells. Cell Host Microbe, 2014; 16:201–214.
24.
HsuJL, van den BoomenDJ, TomasecP, et al.Plasma membrane profiling defines an expanded class of cell surface proteins selectively targeted for degradation by HCMV US2 in cooperation with UL141. PLoS Pathog, 2015; 11:e1004811.
25.
WangECY, PjechovaM, NightingaleK, et al.Suppression of costimulation by human cytomegalovirus promotes evasion of cellular immune defenses. Proc Natl Acad Sci U S A, 2018; 115:4998–5003.
26.
VlahavaVM, MurrellI, ZhuangL, et al.Monoclonal antibodies targeting nonstructural viral antigens can activate ADCC against human cytomegalovirus. J Clin Invest, 2021; 131:e139296.
Al-ZaherAA, MorenoR, FajardoCA, et al.Evidence of anti-tumoral efficacy in an immune competent setting with an iRGD-modified hyaluronidase-armed oncolytic adenovirus. Mol Ther Oncolytics, 2018; 8:62–70.
29.
YuD, JinC, LejaJ, et al.Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors. J Virol, 2011; 85:13114–13123.
30.
Puig-SausC, LabordaE, Rodriguez-GarciaA, et al.The combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model. Cancer Gene Ther, 2014; 21:68–73.
31.
YuD, JinC, RamachandranM, et al.Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures. PLoS One, 2013; 8:e54952.
32.
Uusi-KerttulaH, LegutM, DaviesJ, et al.Incorporation of peptides targeting EGFR and FGFR1 into the adenoviral fiber knob domain and their evaluation as targeted cancer therapies. Hum Gene Ther, 2015; 26:320–329.
33.
Uusi-KerttulaH, DaviesJA, ThompsonJM, et al.Ad5NULL-A20: a tropism-modified, alphavbeta6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies. Clin Cancer Res, 2018; 24:4215–4224.
34.
Uusi-KerttulaH, DaviesJ, CoughlanL, et al.Pseudotyped alphavbeta6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget, 2016; 7:27926–27937.
35.
ManYKS, DaviesJA, CoughlanL, et al.The novel oncolytic adenoviral mutant Ad5–3Delta-A20T retargeted to alphavbeta6 integrins efficiently eliminates pancreatic cancer cells. Mol Cancer Ther, 2018; 17:575–587.
36.
Hulin-CurtisSL, Uusi-KerttulaH, JonesR, et al.Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy. Cancer Gene Ther, 2016; 23:229–234.
37.
RojasLA, CondezoGN, MorenoR, et al.Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery. J Control Release, 2016; 237:78–88.
38.
Rodriguez-GarciaA, SvenssonE, Gil-HoyosR, et al.Insertion of exogenous epitopes in the E3–19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity. Gene Ther, 2015; 22:596–601.
39.
McSharryBP, BurgertHG, OwenDP, et al.Adenovirus E3/19K promotes evasion of NK cell recognition by intracellular sequestration of the NKG2D ligands major histocompatibility complex class I chain-related proteins A and B. J Virol, 2008; 82:4585–4594.
40.
BewigB, SchmidtWE. Accelerated titering of adenoviruses. Biotechniques, 2000; 28:870–873.
41.
StantonRJ, BaluchovaK, DarganDJ, et al.Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. J Clin Invest, 2010; 120:3191–3208.
42.
van der PloegK, ChangC, IvarssonMA, et al.Modulation of human leukocyte antigen-C by human cytomegalovirus stimulates KIR2DS1 recognition by natural killer cells. Front Immunol, 2017; 8:298.
43.
SmitsAH, ZiebellF, JobertyG, et al.Biological plasticity rescues target activity in CRISPR knock outs. Nat Methods, 2019; 16:1087–1093.
44.
YuenG, KhanFJ, GaoS, et al.CRISPR/Cas9-mediated gene knockout is insensitive to target copy number but is dependent on guide RNA potency and Cas9/sgRNA threshold expression level. Nucleic Acids Res, 2017; 45:12039–12053.
45.
WilkinsonGW, AkriggA. Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Res, 1992; 20:2233–2239.
46.
AdikusumaF, PiltzS, CorbettMA, et al.Large deletions induced by Cas9 cleavage. Nature, 2018; 560:E8–E9.
47.
WenW, QuanZ-J, LiS-A, et al.Effective control of large deletions after double-strand breaks by homology-directed repair and dsODN insertion. Genome Biol, 2021; 22:236.
48.
VakulskasCA, DeverDP, RettigGR, et al.A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat Med, 2018; 24:1216–1224.
49.
KleinstiverBP, PattanayakV, PrewMS, et al.High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature, 2016; 529:490–495.
50.
SlaymakerIM, GaoL, ZetscheB, et al.Rationally engineered Cas9 nucleases with improved specificity. Science, 2016; 351:84–88.
LeeJK, JeongE, LeeJ, et al.Directed evolution of CRISPR-Cas9 to increase its specificity. Nat Commun, 2018; 9:3048.
53.
CasiniA, OlivieriM, PetrisG, et al.A highly specific SpCas9 variant is identified by in vivo screening in yeast. Nat Biotechnol, 2018; 36:265–271.
54.
DangY, JiaG, ChoiJ, et al.Optimizing sgRNA structure to improve CRISPR-Cas9 knockout efficiency. Genome Biol, 2015; 16:280.
55.
ChoiEW, SeenDS, SongYB, et al.AdHTS: a high-throughput system for generating recombinant adenoviruses. J Biotechnol, 2012; 162:246–252.
56.
MiciakJJ, HirshbergJ, BunzF. Seamless assembly of recombinant adenoviral genomes from high-copy plasmids. PLoS One, 2018; 13:e0199563.
57.
RuzsicsZ, WagnerM, OsterlehnerA, et al.Transposon-assisted cloning and traceless mutagenesis of adenoviruses: development of a novel vector based on species D. J Virol, 2006; 80:8100–8113.
58.
Muck-HauslM, SolankiM, ZhangW, et al.Ad 2.0: a novel recombineering platform for high-throughput generation of tailored adenoviruses. Nucleic Acids Res, 2015; 43:e50.
59.
JinYH, JooH, LeeK, et al.Streamlined procedure for gene knockouts using all-in-one adenoviral CRISPR-Cas9. Sci Rep, 2019; 9:277.
60.
Ehrke-SchulzE, SchiwonM, LeitnerT, et al.CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes. Sci Rep, 2017; 7:17113.
61.
NakanishiT, MaekawaA, SuzukiM, et al.Construction of adenovirus vectors simultaneously expressing four multiplex, double-nicking guide RNAs of CRISPR/Cas9 and in vivo genome editing. Sci Rep, 2021; 11:3961.
62.
CunliffeTG, BatesEA, ParkerAL. Hitting the target but missing the point: recent progress towards adenovirus-based precision virotherapies. Cancers, 2020; 12:3327.
63.
BradshawAC, ParkerAL, DuffyMR, et al.Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. PLoS Pathog, 2010; 6:e1001142.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
